Treace Medical Concepts, Inc. (NASDAQ:TMCI) Just Reported, And Analysts Assigned A US$8.35 Price Target

Shareholders of Treace Medical Concepts, Inc. (NASDAQ:TMCI) will be pleased this week, given that the stock price is up 15% to US$6.13 following its latest second-quarter results. Revenue hit US$47m in line with forecasts, although the company reported a statutory loss per share of US$0.28 that was somewhat smaller than the analysts expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Treace Medical Concepts after the latest results.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

After the latest results, the six analysts covering Treace Medical Concepts are now predicting revenues of US$227.1m in 2025. If met, this would reflect an okay 6.3% improvement in revenue compared to the last 12 months. Per-share losses are predicted to creep up to US$0.81. Before this latest report, the consensus had been expecting revenues of US$227.0m and US$0.80 per share in losses.

View our latest analysis for Treace Medical Concepts

The analysts trimmed their valuations, with the average price target falling 15% to US$8.35, with the ongoing losses seemingly weighing on sentiment, despite no real changes to the earnings forecasts. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Treace Medical Concepts, with the most bullish analyst valuing it at US$12.00 and the most bearish at US$6.00 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that Treace Medical Concepts' revenue growth is expected to slow, with the forecast 13% annualised growth rate until the end of 2025 being well below the historical 19% p.a. growth over the last three years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 8.2% annually. Even after the forecast slowdown in growth, it seems obvious that Treace Medical Concepts is also expected to grow faster than the wider industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.

With that in mind, we wouldn't be too quick to come to a conclusion on Treace Medical Concepts. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Treace Medical Concepts going out to 2027, and you can see them free on our platform here..

That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Treace Medical Concepts , and understanding it should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.